Avelumab
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphomas Non-Hodgkin's B-Cell
Conditions
Lymphomas Non-Hodgkin's B-Cell
Trial Timeline
Jul 21, 2017 → Jul 1, 2025
NCT ID
NCT03244176About Avelumab
Avelumab is a phase 1 stage product being developed by Merck for Lymphomas Non-Hodgkin's B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT03244176. Target conditions include Lymphomas Non-Hodgkin's B-Cell.
What happened to similar drugs?
0 of 2 similar drugs in Lymphomas Non-Hodgkin's B-Cell were approved
Approved (0) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03089658 | Pre-clinical | Completed |
| NCT06412848 | Pre-clinical | Active |
| NCT05600127 | Phase 2 | Recruiting |
| NCT05431777 | Pre-clinical | Completed |
| NCT05366725 | Pre-clinical | Completed |
| NCT04822350 | Pre-clinical | Completed |
| NCT03815643 | Phase 3 | Active |
| NCT03514719 | Phase 1 | Completed |
| NCT03568097 | Phase 2 | UNKNOWN |
| NCT03827044 | Phase 3 | Terminated |
| NCT03674424 | Phase 2 | Completed |
| NCT03439501 | Phase 2 | UNKNOWN |
| NCT03147404 | Phase 2 | Completed |
| NCT03352934 | Phase 2 | Completed |
| NCT03389126 | Phase 2 | Completed |
| NCT03278379 | Phase 2 | Completed |
| NCT03278405 | Phase 1/2 | Completed |
| NCT03403777 | Phase 2 | Completed |
| NCT03491345 | Phase 2 | UNKNOWN |
| NCT03244176 | Phase 1 | Active |
Competing Products
20 competing products in Lymphomas Non-Hodgkin's B-Cell